Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416453 | 1.00 | PARP1 (0.73) | PARP1AR | |
| SCHEMBL15218259 | 0.88 | PARP1 (0.69) | PARP1AR | |
| SCHEMBL12955528 | 0.86 | PARP1 (0.72) | PARP1AR | |
| SCHEMBL12955358 | 0.85 | PARP1 (0.72) | PARP1AR | |
| SCHEMBL86935 | 0.84 | PARP1 (0.56) | PARP1AR | |
| SCHEMBL30415143 | 0.84 | PARP1 (0.60) | PARP1AR | |
| SCHEMBL29007084 | 0.84 | PARP1 (0.60) | PARP1AR | |
| SCHEMBL4572851 | 0.83 | PARP1 (0.60) | PARP1AR | |
| SCHEMBL13265557 | 0.83 | PARP1 (0.76) | PARP1AR | |
| SCHEMBL863462 | 0.83 | AR (1.00) | PARP1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340519-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4644385-A1 | TIPARP INHIBITOR COMPOUNDS | AbbVie Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250333394-A1 | Tiparp Inhibitor Compounds | ABBVIE INC. (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4624459-A2 | RADIOLABELLED COMPOUND | Oxford University Innovation Limited (GB) | 2025-10-01 | — | — | EP | disclosed |
| CN-116143700-B | Phthalazinone compound, and preparation method and application thereof | 沈阳药科大学 | 2024-06-28 | — | — | CN | disclosed |
| CN-116143700-A | Phthalazinone compound, and preparation method and application thereof | 沈阳药科大学 | 2023-05-23 | — | — | CN | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3284743-B1 | HETEROCYCLIC-IMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECH CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3284743-B1 | HETEROCYCLIC-IMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECH CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-7449464-B2 | 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| CN-1788000-A | Phthalazinone derivatives | KUDOS PHARM LTD (GB) | 2006-06-14 | — | — | CN | disclosed |
| EP-1633724-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20050059663-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059663-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | PARP1 3029/4885AR 142/4885 |
| US-20250340519-A1 | RADIOLABELLED COMPOUND | PARP3, PARP2, PARP1 | PARP1 3/4885AR 112/4885 |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885AR 667/4885 |
| US-20060149059-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | PARP1 3176/4885AR 130/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | PARP1 3176/4885AR 130/4885 |
| US-20250333394-A1 | Tiparp Inhibitor Compounds | TIPARP, TIPRL, TPP1 | PARP1 117/4885AR 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.